Compare KINS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KINS | FATE |
|---|---|---|
| Founded | 1886 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.5M | 260.0M |
| IPO Year | 2013 | 2013 |
| Metric | KINS | FATE |
|---|---|---|
| Price | $22.93 | $1.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.72 |
| AVG Volume (30 Days) | 93.7K | ★ 1.5M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 94.59 | 29.88 |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $214,867,301.00 | $6,646,000.00 |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $15.85 | $18.72 |
| P/E Ratio | $12.49 | ★ N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.83 | $0.95 |
| 52 Week High | $23.42 | $3.23 |
| Indicator | KINS | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 23.18 |
| Support Level | $18.35 | $1.07 |
| Resistance Level | N/A | $1.38 |
| Average True Range (ATR) | 0.86 | 0.16 |
| MACD | 0.33 | -0.07 |
| Stochastic Oscillator | 86.05 | 7.35 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.